Key Takeaways
- Revenue crossed $1 bn, beat guidance: FY26 revenue grew 16.6% YoY, exceeding the company's own target, driven by 22% international growth and resilient domestic performance.
- Domestic Q4 hit by Zuventus restructuring: Domestic growth slowed to 5.2% in Q4 as the Zuventus portfolio and team reorganization triggered higher field-force attrition, masking 9-10% base business growth.
- Margins expanded despite investment: EBITDA margin improved 80 bps to 19.4% for FY26, absorbing a 50 bps R&D step-up, while adjusted PAT margin rose 189 bps to 10.9%.
- Semaglutide bet is now live: The exclusive Novo Nordisk partnership for Poviztra is scaling with 1,000 reps, and a price cut in April 2026 has sharpened its positioning against generics.
- What to watch next quarter: Whether Zuventus's April recovery sustains through Q1 FY27, the pace of Amphotericin B's European rollout, and any margin impact if elevated solvent and freight costs persist beyond 1-2 quarters.
Domestic Business: The Zuventus Overhang
- Core business intact: Excluding Zuventus, full-year base business growth would have been close to 9-10%, consistent with the first nine months, led by women's health, cardiac, CNS and oncology.
- Zuventus disruption mechanics: The minority stake buyout and departure of the former promoter in October triggered a new management team, a full portfolio relook, and team restructuring in late Q3 and Q4. The resulting field-force attrition hit acute sales disproportionately because short-treatment therapies lose volume quickly when rep coverage gaps open.
- Recovery signal: Management stated April performance is right on target versus internal expectations, with the restructuring starting to pay dividends over the last 45 to 60 days.
- Market share: Overall market share was flattish for the year, weighed down by the Q4 disruption.
Satish Mehta: "We'll be back on track. And again, the other thing that I would like to say is that as Zuventus is concerned over a period of time, we have built some very strong brands. So that should also take us through."
International Markets: The Growth Engine
- Scale and momentum: International revenue grew 22% to ₹5,177 crores in FY26, with Q4 accelerating to 25.7% growth. Europe led at 35.8%, Canada at 28.6%, and emerging markets at 15.5% with both ARV and non-ARV segments strong.
- Europe's building blocks: Growth rests on three legs: the base business, the Manx portfolio acquisition scaling up, and Amphotericin B launches in select European markets in H2 FY26. Management expects mid-teens CAGR in Europe over the next two years.
- Canada's dual semaglutide play: The Mantra subsidiary has partnered with Dr. Reddy's to launch semaglutide, expected in Q2 FY27, while Emcure is also filing its own product for the midterm.
- Gross margin tailwind: Q4 gross margin improved 160 bps to 59.4%, attributed to better business mix, especially new international launches. Full-year gross margins are expected to remain around 60%.
Portfolio & Pipeline: Biologics, Licenses and NASH
- Poviztra (semaglutide) positioning: The product is a patented rDNA biologic, not a synthetic, which management uses as the scientific differentiator against generics. After an initial market-shaping phase, a price cut in April 2026 created what management calls a sweet spot versus generics, and 1,000 sales reps are now promoting it.
- Sanofi OAD expansion: The partnership expanded to include oral anti-diabetic brands Amaryl and Cetapin, strengthening the cardiac and metabolic basket.
- Roche nephrology distribution: A distribution agreement for select nephrology and transplant medications began billing from April 1, with an annualized portfolio size under ₹50 crores and no upfront payment.
- Bevacizumab: Received SEC endorsement for wet AMD; launch planned in H1 FY27, pending final approval.
- Lenacapavir: DMF filed; Emcure is one of six global voluntary licensees for Gilead's HIV drug, with product registration expected in FY27.
- NASH: SEC has cleared permission; launch timing is uncertain but described as "any time."
- ADC pipeline: Two tracks: a biosimilar ADC with a potentially shorter pathway if Indian regulators waive Phase III, and an innovative ADC with a longer horizon. No commercialization timeline given.
Satish Mehta: "As far we are concerned, we'll talk about the merit of the product, which is rDNA product, not synthetic, backed up by a lot of clinical data. So we'll be differentiating ourselves on the back of science, we'll be talking to the doctor."
Margins & Costs: Expansion with Eyes on Input Prices
- FY26 margin walk: EBITDA margin improved 80 bps to 19.4% despite a 50 bps increase in R&D investment to 4.2% of revenue. Operating leverage and productivity gains did the heavy lifting, partly offset by the Sanofi OAD contribution.
- Field-force productivity: Revenue per medical representative rose from ₹5.4 lakhs to ₹7 lakhs over two years.
- Geopolitical cost pressure: Solvent prices have shot up and API solvents face availability issues industry-wide. Insurance and freight costs have also risen on longer shipping routes. Emcure carries 1-2 quarters of inventory, so the impact is contained for now; sustained elevation beyond that would need to be assessed.
- Pricing power as a buffer: Management argues its differentiated portfolio gives better ability to ask for higher prices than a pure generics player, and the domestic industry body IPA has already reached out for a price hike.
Satish Mehta: "This is an industry-wide problem, not necessarily restricted to one company. And the advantage that we will have is that we are not in a purely generic-generic market because we have differentiated products."
Capital Allocation & Strategy
- Net debt rose to ₹1,054 crores, driven by pay-outs for the Manx portfolio acquisition and the Zuventus minority stake buyout.
- Capex for FY27: Guided at ₹400-425 crores.
- In-licensing stays selective: The primary focus is organic growth, but in-licensing will continue where accretive and value-adding, as demonstrated by the Roche nephrology deal with no upfront payment.
- AI investments: Being deployed across R&D, manufacturing, support functions and marketing (sales force effectiveness, graphics, brand plans), with real benefits expected to accrue over the next 2-3 years.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Low to mid-teen growth | FY27 |
| EBITDA margin expansion | 75 to 100 bps expansion, assuming stable regulations and macro conditions | FY27 |
| Gross margin | Remain around 60% | FY27 |
| Domestic growth | Grow faster than industry (industry expected at 8-9%); low double-digits | FY27 |
| Europe growth | Mid-teens CAGR | Over next 2 years |
| Bevacizumab launch | Launch in India | H1 FY27, pending approval |
| Lenacapavir registration | Seek product registration | FY27 |
| Amphotericin B expansion | Expand to Europe and rest of world; significant contribution expected | FY27 |
| Capex | ₹400-425 crores | FY27 |
| Employee expenses | Around 10% of revenue | FY27 |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue from operations | ₹2,470 cr, up 16.7% YoY |
| Domestic revenue | ₹977 cr, up 5.2% YoY; softness due to Zuventus restructuring |
| International revenue | ₹1,493 cr, up 25.7% YoY |
| Gross margin | 59.4%, up 160 bps YoY from 57.8% |
| EBITDA (excl other income) | ₹485 cr, up 24.5% YoY |
| EBITDA margin | 19.7%, up from 18.4% in Q4 FY25 and 19.5% in Q3 FY26 |
| Adjusted PAT | ₹279 cr, up 36% YoY; adjusted PAT margin 11.3%, up 160 bps |
| Reported PAT | ₹244 cr, PAT margin 9.9% |
| Net debt | ₹1,054 cr as of March 31, 2026 |
| FY27 revenue growth guidance | Low to mid-teen growth, assuming USD:INR at 92 |
| FY27 EBITDA margin expansion guidance | 75 to 100 bps expansion, assuming stable regulations and macro conditions |
| Domestic business growth ex-Zuventus (Q4) | Less than 8% |
| Field force strength | Close to 4,000 medical representatives |
| Field productivity | ₹7 lakhs per MR, up from ₹5.4 lakhs two years ago |
| R&D spend (FY26) | ₹383.5 cr, 4.2% of revenue, up 50 bps YoY |